Kivioja et al. (2019) reported that a combination of Src/Abl-inhibitor dasatinib and BCL-2 inhibitor navitoclax produces a synergistic effect against NUP98-NSD1+/FLT3-ITD+ AML cells. Here, NUP98 is linked to acute myeloid leukemia.